Skip to content
Pharma Battle: NVO vs. HIMS – Who’s Right? episode artwork

Feb 13, 2026 53 min

Pharma Battle: NVO vs. HIMS – Who’s Right?

from The Big Skinny Hosted by Launch Live Now

This week on The Big Skinny, Lou Basenese goes head-to-head with Futurum Group's CEO Daniel Newman in a special debate episode sparked by a viral tweet defending Hims & Hers Health, Inc. (HIMS) compounding Novo Nordisk’s (NVO) leading drug. Is HIMS a legitimate healthcare disruptor – or underestimating the power of Big Pharma and regulatory risk? Lou and Dan break down what this controversy means for investors, the real economics behind GLP-1 drugs, and whether disruption always wins in healthcare. Then Lou widens the lens to the broader market, tackling the state of the AI trade and the recent wave of sharp software stock selloffs. Are these cracks forming beneath the surface — or healthy resets in a long-term bull cycle? No fluff. No fear-mongering. Just a data-driven debate about where risk and opportunity really lie.

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

Pharma Battle: NVO vs. HIMS – Who’s Right?

0:00 53:02

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of The Big Skinny?

This episode is 53 minutes long.

When was this The Big Skinny episode published?

This episode was published on February 13, 2026.

Can I download this The Big Skinny episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.